Company / Operating Income per Share
Ultragenyx Pharmaceutical Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$5.78
FY2025
5-year range
-$9.36 / -$5.78
FY2021-FY2025
Trend
+11.2%
vs FY2024
Sector context
#176 of 201
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s operating income per share of $-5.78 is lower than 88% of companies in the Health Care sector (FY2025). Operating Income per Share has increased for 3 consecutive years, from $-9.36 in FY2022 to $-5.78 in FY2025.
Based on SEC 10-K filings.
-5.78 in FY2025.
Improved from $-8.11 to $-5.78 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 201This company -$5.78 Sector average -$28.56
▼
+79.7% above sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s operating income per share has grown for 3 consecutive years.
- In FY2025, operating income per share increased 11.2% year-over-year.
- Ranks #176 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.78 | +11.2% |
| FY2024 | -$6.51 | +19.7% |
| FY2023 | -$8.11 | +13.4% |
| FY2022 | -$9.36 | -47.4% |
| FY2021 | -$6.35 | +1.1% |
| FY2020 | -$6.42 | +0.7% |
| FY2019 | -$6.47 | +23.1% |
| FY2018 | -$8.41 | -134.7% |
| FY2017 | -$3.58 | -145.3% |
| FY2016 | -$1.46 | +63.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026